Pharmaceutical advertising compliance
Pharmaceutical advertising compliance is not a native risk category for Energy, Power & Commodities firms, but companies operating dual-market portfolios or sponsoring consumer-facing health and wellness products fall squarely under the jurisdiction of the U.S. Food and Drug Administration's Office of Prescription Drug Promotion and the U.S. Federal Trade Commission's health claims enforcement framework. The Federal Energy Regulatory Commission does not regulate drug advertising directly, but energy companies that co-brand or white-label health products have drawn FTC scrutiny under deceptive advertising statutes. Compliance teams at integrated commodity firms are cross-mapping marketing approval workflows against FTC's revised Health Products Compliance Guidance (2023) before campaigns reach retail channels.
Watch
- FTC Health Products Compliance Guidance (2023): revised substantiation standard for health claims in consumer marketing
- FDA OPDP untitled letters issued to non-pharma parent companies with pharma subsidiaries
- State attorneys general coordinating multi-state actions on misleading energy-health product advertising
- Whether your firm's commodity trading desk sponsors health-adjacent consumer brands triggering FDA oversight
Recent material activity in Energy, Power & Commodities
Active monitoring in place across Energy, Power & Commodities. Material developments related to pharmaceutical advertising compliance will appear here as they are published.